posttransplantation lymphoproliferative disorder

posttransplantation lymphoproliferative disorder

A complication of 1-10% of organ transplant recipients, which may be poly- or monoclonal; most affected cells contain EBV, usually latent; post-transplantation Pts at risk for PTLD can be identified by detecting expression–as small mRNA of the EBER-1 gene; most cases that occur in solid organ recipients are of host origin
References in periodicals archive ?
Imaging features of posttransplantation lymphoproliferative disorder in pancreas transplant recipients.
Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
Due to chronic immunosuppression of liver transplant recipients, posttransplantation lymphoproliferative disorder (PTLD), which is often associated with infection from Epstein-Barr virus (EBV), and non-Hodgkin's lymphoma are becoming more common.
It includes infections as well as neoplasms, such as lymphoma, posttransplantation lymphoproliferative disorder, meningioma, and metastases.
Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscamet alone in an adult after simultaneous heart and renal transplantation.
CT findings in posttransplantation lymphoproliferative disorder of renal transplants.
The specimens represented numerous histopathologic diagnoses, including non-Hodgkin lymphoma, posttransplantation lymphoproliferative disorder, chronic lymphocytic leukemia/small lymphocytic lymphoma, and benign lymphoid tissue, as well as cell lines obtained from reliable vendors.
Posttransplantation lymphoproliferative disorder complicates approximately 1% of renal transplant patients, with a spectrum of disease ranging from mild diffuse polyclonal lymphadenopathy to malignant monoclonal lymphoma.
The unusual presentation of this case also raised the possibility of posttransplantation lymphoproliferative disorder (PTLD).
Posttransplantation lymphoproliferative disorder (PTLD) occurs in 2% to 10% of adults, with a higher incidence in children and may present as early as 1 month posttransplant.
Posttransplantation lymphoproliferative disorder involvement of the allograft may accelerate dysfunction of an organ that is already compromised due to attack by the host immune system.
Posttransplantation lymphoproliferative disorder (PTLD) is a feared complication that may occur with any type of allogenic transplant and affects 2% to 5% of solid-organ transplant patients.
Full browser ?